JAK抑制剂治疗系统性硬化症的真实世界安全性与有效性:EUSTAR队列倾向匹配研究
结果显示JAKi在肺功能、皮肤纤维化、关节肿胀及疾病进展方面与标准免疫抑制剂相当,但药物持久性差且存在安全性顾虑。
要点
- JAKi治疗SSc的疗效与MMF、RTX、MTX相当,肺功能和皮肤纤维化稳定。
- JAKi组永久停药率达39%,药物持久性差是主要限制因素。
核心结论
- JAKi在SSc中的有效性与其他标准免疫抑制剂相似,但药物持久性和安全性问题可能限制其临床应用。
研究设计与样本
- 欧洲硬皮病试验与研究组(EUSTAR)队列的纵向回顾性研究,采用最近邻倾向评分匹配比较JAKi治疗者与MMF、RTX、MTX治疗者。
主要发现
- 98.7患者年中共记录23例不良事件,包括12例感染、7例实验室异常和3例恶性肿瘤。
- 12个月时肺功能保持稳定(平均FVC%变化+1.7%,P=0.530),dcSSc患者mRSS平均变化-1.8。
- 基线有滑膜炎者肿胀关节数中位变化-1(P=0.052),数字溃疡复发率和疾病进展事件与匹配的免疫抑制组相当。
- 未观察到新的钙质沉着负担。
临床怎么用
- JAKi可作为SSc患者标准免疫抑制治疗的替代选择之一,但需密切监测感染和恶性肿瘤风险。
- 治疗前应充分评估药物持久性相关因素,并向患者说明停药可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: JAK inhibitors (JAKi) have shown promising effects in early-phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. METHODS: A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was performed. JAKi-treated patients were compared to patients receiving mycophenolate mofetil (MMF), rituximab (RTX), and methotrexate (MTX) using nearest-neighbor propensity score matching. Primary outcomes were safety and drug survival. Secondary outcomes included change in forced vital capacity (FVC), change in modified Rodnan skin scores (mRSS) in patients with diffuse cutaneous SSc (dcSSc), improvement in swollen joint count, digital ulcer (DU) recurrence, and a composite disease progression endpoint. Comparative analyses were performed using generalized linear models and time-to-event methods, including Kaplan-Meier and restricted mean survival time analyses. RESULTS: Thirty-six JAKi-treated patients from 19,601 were included (median drug exposure 37 months). Median disease duration was seven years, and 33% had dcSSc. For 98.7 patient-years, 23 adverse events were recorded, including 12 infections, 7 laboratory abnormalities, and 3 malignancies. Treatment was discontinued permanently in 39% and transiently in 19%. At 12 months, lung function remained stable (mean FVC% +1.7%, P = 0.530) during follow-up and skin fibrosis showed a numerical improvement (mean mRSS -1.8) in patients with dcSSc. These results were comparable to those observed in MMF, RTX, and MTX groups. Swollen joint counts decreased in patients with baseline synovitis (median change -1, P = 0.052). DU recurrence rates and disease progression events were comparable to those in matched immunosuppressive groups. No new calcinotic burden was observed. CONCLUSION: JAKi showed similar effectiveness compared to standard-of-care immunosuppressants. However, drug persistence and safety concerns may be a limiting factor in patients with SSc.
引用
- Di Donato S, Truchetet ME, Minerba M, et al. Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort. Arthritis Care Res (Hoboken). 2026. PMID: 42294821. doi:10.1002/acr.80100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。